SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
SS-31 is being researched for skin applications. Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactiv. Common dosages for this use range from 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV daily subcutaneous or weekly IV infusion.
Can SS-31 Help With Skin?
SS-31 (Elamipretide (SS-31)) is being researched for skin applications based on its mechanism as a Mitochondrial-targeting tetrapeptide.
Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactive oxygen species production, increases ATP generation, and prevents apoptosis through mitochondrial outer membrane stabilization.
What Does the Research Show for SS-31 and Skin?
FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
The relevance to skin specifically comes from SS-31's effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What Protocol Is Used for Skin?
For skin applications, the standard SS-31 protocol is 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion for 12-48 weeks in clinical trials.
Some researchers adjust dosing based on the specific skin application — see our SS-31 dosage guide for full protocol details.
Can Stacking Improve Skin Results?
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.
What Side Effects Apply to Skin Use?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Side effects are generally consistent regardless of the specific application. See our SS-31 side effects guide for details.
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Bottom Line: SS-31 for Skin
SS-31 shows preliminary research potential for skin. Standard protocols (4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV, daily subcutaneous or weekly IV infusion, 12-48 weeks in clinical trials) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.